Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Chememan PCL's earnings before interest and taxes (EBIT) for the
three
months ended in Mar. 2026 was ฿218 Mil.
Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ฿550 Mil.
EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
Chememan PCL's annualizedROC % for the quarter that ended in Mar. 2026 was 11.86%.
Chememan PCL's annualizedROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 18.67%.
EBIT is also linked to Joel Greenblatt's definition of earnings yield.
Chememan PCL's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 10.50%.
Chememan PCL (BKK:CMAN) EBIT Explanation
1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
Chememan PCL's annualizedROC % for the quarter that ended in Mar. 2026 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chememan PCL EBIT Related Terms
Chememan PCL EBIT Historical Data
* Premium members only.
The historical data trend for Chememan PCL's EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Specialty Chemicals subindustry, Chememan PCL's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chememan PCL EV-to-EBIT vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Chememan PCL's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Chememan PCL's EV-to-EBIT falls into.
EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.
EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ฿550 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chememan PCL (BKK:CMAN) has a EBIT of ฿550 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Chememan PCL.
Is Chememan PCL's EBIT too high?
Chememan PCL's current EBIT is ฿550 Mil. Overall, Chememan PCL has a GF Score™ of 71/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Chememan PCL's EBIT compare to LIN and SHW?
Chememan PCL's EBIT of ฿550 Mil can be compared against companies in the Chemicals industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Chemicals company?
A good EBIT depends on the Chemicals industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Chememan PCL. Chememan PCL's current EBIT is ฿550 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chememan PCL stock overvalued right now?
Based on GuruFocus' analysis, Chememan PCL (BKK:CMAN) is currently considered Modestly Overvalued. The stock's GF Value™ is ฿2.18, compared to a current price of ฿2.84 — trading 30.3% above its estimated fair value. The current EBIT is ฿550 Mil. Chememan PCL's overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Chememan PCL (BKK:CMAN), the current EBIT is ฿550 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chememan PCL (BKK:CMAN) Overvalued in 2026?
Based on GuruFocus' analysis, Chememan PCL stock appears to be overvalued.
The current stock price of ฿2.84 is trading 30.3% above its estimated GF Value™ of ฿2.18.
GuruFocus considers Chememan PCL to be Modestly Overvalued.
Key valuation signals for BKK:CMAN:
EBIT: ฿550 Mil
GF Value™: ฿2.18 vs. price of ฿2.84 (30.3% above fair value)
No single metric tells the full story. See the BKK:CMAN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chememan PCL is engaged in the manufacture and distribution of mineral lime products. The company transforms natural resources into basic and specialty chemicals and synthetic products. Its product offerings include quicklime (Calcium Oxide, CaO), hydrated lime (Calcium Hydroxide, Ca(OH)2), as well as chemical grade and construction limestone (Calcium Carbonate, CaCO3). The group's business operations involve two geographic segments: the company, which is incorporated in Thailand, manufactures and distributes minerals and chemicals; and the subsidiaries, which are incorporated overseas, manufacture and distribute minerals and chemicals. The majority of the group's revenue is derived from its business in Thailand, and the rest from overseas markets.
71GF Score
Get the complete analysis for BKK:CMAN
EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:CMAN has been successfully added to your 
